KPV: an α-MSH fragment with almost no human trial record
KPV is discussed for gut and skin inflammation. The 2026 compounding debate made it famous. The clinical literature did not suddenly grow.
KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte-stimulating hormone. Cell and animal papers describe anti-inflammatory effects, including in colitis models.
Why it surged in 2026
In July 2026 an FDA advisory committee discussed whether KPV could be used by compounding pharmacies. That is a regulatory process about bulk ingredients, not a new efficacy trial. A committee vote is not an approval and is not a human outcome study.
What the literature still is
Most KPV papers remain preclinical. There is no large randomized trial establishing KPV as a treatment for inflammatory bowel disease, skin disease, or “gut healing” in people.
Bottom line
Evidence ladder: Animal. Interest is high; controlled human evidence is not.
Sources
Educational content only — not medical advice. See our Medical disclaimer and Editorial policy.